<DOC>
	<DOCNO>NCT01688492</DOCNO>
	<brief_summary>The purpose study find effect , good and/or bad , take ipilimumab abiraterone acetate plus prednisone patient prostate cancer . Abiraterone acetate plus prednisone drug low testosterone ( testosterone stimulate prostate cancer growth ) . Abiraterone acetate plus prednisone treatment patient prostate cancer . Abiraterone acetate plus prednisone use together ipilimumab . This study test work together . Each patient receive abiraterone acetate , prednisone ipilimumab .</brief_summary>
	<brief_title>Combining Ipilimumab With Abiraterone Acetate Plus Prednisone Chemotherapy Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Chemotherapy immunotherapynaïve patient progressive metastatic CRPC eligible . Age 18 old , willing able provide inform consent . Histologically cytologically confirm adenocarcinoma prostate either MSKCC participate site . Castrate serum testosterone level , ≤ 1.73 nmol/L ( 50 ng/dL ) , Screening visit . Ongoing androgen deprivation therapy GnRH analogue bilateral orchiectomy ( ie , surgical medical castration ) . Metastatic disease imaging ( e.g. , bone scan , CT , MRI ) . Patients whose disease spread limit regional pelvic lymph node eligible . If lymph node metastasis evidence metastasis , must ≥ 2 cm diameter . Progressive disease study entry define PSA and/or radiographic criterion accord PCWG2 . Karnofsky performance status ≥80100 , estimate life expectancy ≥ 6 month . Toxicities related prior therapy must either return ≤ Grade 1 baseline deem irreversible opinion Investigator worsen . Able swallow study drug comply study requirement . History another malignancy within previous 5 year nonmelanomatous skin cancer . Absolute neutrophil count &lt; 1,500/μL , platelet count &lt; 75,000/μL , hemoglobin &lt; 5.6 mmol/L ( 9 g/dL ) Screening visit . ( NOTE : patient may receive growth factor within 7 day blood transfusion within 28 day hematologic laboratory value obtain Screening visit ) . Serum bilirubin ≥ 1.5 x ULN patient Gilbert 's disease , ≥3 mg/dL Screening visit ; AST ALT ≥ 2.5 x ULN , ( patient know liver metastasis , AST ALT ≤ 5 x ULN allow ) Screening visit . Creatinine &gt; 177 μmol/L ( 2 mg/dL ) , albumin &lt; 30 g/L ( 3.0 g/dL ) , potassium ≤ 3.5 mEq/L Screening visit . Clinically significant cardiovascular disease include myocardial infarction within 6 month , uncontrolled angina within 3 month , congestive heart failure New York Heart Association ( NYHA ) class 3 4 , uncontrolled hypertension indicate systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 95 mmHg Screening visit . Major surgery radiation therapy within 4 week enrollment ( Day 1 Visit ) . Treatment antiandrogens ( eg , bicalutamide , flutamide , nilutamide ) within 4 week enrollment ( Day 1 visit ) . Concomitant therapy agent list Section 4.3.2 prohibit . History progression prostate cancer disease receive ketoconazole . Prior use participation clinical trial investigational agent block androgen synthesis ( eg , abiraterone acetate , TAK700 , TAK683 , TAK448 ) , chemotherapy , immunological agent ( eg , immune modulators , cytokine , vaccine , antibodydelivered chemotherapy ) . The use denosumab bone metastasis permit . Known allergy compound investigation . The patient uncontrolled significant medical condition cancer , would prevent participation study make protocol unreasonably hazardous , opinion investigator , include limited : Autoimmune disease : Patients history inflammatory bowel disease , include ulcerative colitis Crohn 's Disease , exclude study , patient history symptomatic disease ( eg , rheumatoid arthritis , systemic progressive sclerosis [ scleroderma ] , systemic lupus erythematosus , autoimmune vasculitis [ eg , Wegener 's granulomatosis ] ) ; motor neuropathy consider autoimmune origin ( eg , GuillainBarre syndrome myasthenia gravis ) . Known suspected brain metastasis , untreated leptomeningeal disease . Active infection medical condition would make prednisone use contraindicate . Active symptomatic viral hepatitis chronic liver disease .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>MDX-010 ( Ipilimumab )</keyword>
	<keyword>ABIRATERONE ACETATE ( CB 7630 )</keyword>
	<keyword>PREDNISONE</keyword>
	<keyword>Immunotherapy-naïve</keyword>
	<keyword>castration resistant prostate cancer ( CRPC )</keyword>
	<keyword>12-120</keyword>
</DOC>